CY2200159T2 - 2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη - Google Patents

2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη

Info

Publication number
CY2200159T2
CY2200159T2 CY20082200002T CY082200002T CY2200159T2 CY 2200159 T2 CY2200159 T2 CY 2200159T2 CY 20082200002 T CY20082200002 T CY 20082200002T CY 082200002 T CY082200002 T CY 082200002T CY 2200159 T2 CY2200159 T2 CY 2200159T2
Authority
CY
Cyprus
Prior art keywords
methyl
thiazolidinodione
meleine
butaniodioic
pyridinylamino
Prior art date
Application number
CY20082200002T
Other languages
English (en)
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of CY2200159T2 publication Critical patent/CY2200159T2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20082200002T 2006-05-09 2008-02-18 2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη CY2200159T2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06252444A EP1854794A1 (en) 2006-05-09 2006-05-09 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Publications (1)

Publication Number Publication Date
CY2200159T2 true CY2200159T2 (el) 2010-07-28

Family

ID=36997726

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20082200002T CY2200159T2 (el) 2006-05-09 2008-02-18 2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη

Country Status (4)

Country Link
EP (2) EP2270007A1 (el)
CY (1) CY2200159T2 (el)
DE (1) DE06252444T8 (el)
ES (1) ES2294980T1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050595A2 (en) * 2007-10-17 2009-04-23 Medichem, S.A. An improved process for preparing a 2,4-thiazolidinedione derivative
WO2010013141A2 (en) * 2008-08-01 2010-02-04 Actavis Group Ptc Ehf Substantially pure rosiglitazone hydrogen sulfate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery

Also Published As

Publication number Publication date
DE06252444T8 (de) 2009-03-19
EP2270007A1 (en) 2011-01-05
ES2294980T1 (es) 2008-04-16
EP1854794A1 (en) 2007-11-14
DE06252444T1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
CY2018031I2 (el) Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης
CY2015043I1 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
LTC2076501I2 (lt) 3-[5-(2-fluorfenil)-[1,2,4]oksadiazol-3-il]benzenkarboksirūgšties kristalinės formos
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
JP2011021016A5 (el)
DK2300461T3 (da) Cycliske inhibitorer af 11beta-hydroxysteroid-dehydrogenase 1
BRPI0908731A2 (pt) formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
IL195882A (en) Crystalline forms of derivatives of (1 s) –1, 5 – anhydro – 1– c - (3 - ((phenyl) methyl) phenyl) - d -glucitol with amino acids and their use in the treatment of diabetes
DK2049522T3 (da) Hepatitis c-virusinhibitorer
IL220212A (en) Derivatives 5 - [(2-Aminopyrimide-4-Yl) Methylidan] -3,1-Thiazolidine-4,2-Discussion and Pharmaceutical Preparations Containing Them
IL216349A (en) Annals 4– (1-carboxy-ethylcarbamoyl) –4– (5– [1,12] diethylan-3-ram-pentanoylamino) -butyric acid and preparations containing them
DK1986928T3 (da) Palle
ATE517101T1 (de) Als mmp-inhibitoren verwendete hydantoinderivate
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
ATE534374T1 (de) Orale zubereitung mit pioglitazon
DK2102192T3 (da) Racemisk ilaprazol i fast form
PL384446A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
CL2007002422A1 (es) Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3,1,0]-hexano, solvatos, hidratos y forma cristalina; composicion farmaceutica que comprende a dicho compuesto;
PT1740583E (pt) Derivados de oxadiazolona como agonistas de ppar-delta
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
DK2125714T3 (da) Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid
DK2022497T3 (da) Oral sammensætning, omfattende 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxyphenylpropionsyre eller salt deraf
CY2200159T2 (el) 2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet